Determination of serum zinc-alpha-2-glycoprotein in patients with metabolic syndrome by a new ELISA.
To develop an assay for the determination of ZAG in human serum, and to investigate its clinical relevance as a marker of metabolic syndrome. A new sandwich ELISA was introduced and clinically tested. ZAG serum level did not differentiate healthy subjects (27.4+/-8.3 mg/L; N=132) from patients with metabolic syndrome (24.9+/-8.1; N=92). ZAG correlated with glucose, creatinine and uric acid. The immunoassay offers a new research tool for glucose metabolism.